Paper31209005
Verapamil Improves the Activity of Bedaquiline against Mycobacterium abscessus In Vitro and in Macrophages.
Viljoen A and 6 others. Antimicrob Agents Chemother, 2019. Cited by 22 papers, by iCite.
Cite this record
ConductScience Library. Verapamil Improves the Activity of Bedaquiline against Mycobacterium abscessus In Vitro and in Macrophages. Papers, record 31209005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31209005
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Verapamil Improves the Activity of Bedaquiline against Mycobacterium abscessus In Vitro and in Macrophages.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Diarylquinolines | Major topic |
| Mycobacterium Infections, Nontuberculous | Major topic |
| Mycobacterium abscessus | Major topic |
| Verapamil | Major topic |
| Antitubercular Agents | |
| Bacterial Proteins | |
| Cell Line | |
| Drug Resistance, Bacterial | |
| Drug Synergism | |
| Humans | |
| Macrophages | |
| Microbial Sensitivity Tests | |
| Mutation |
Source PubMed
References26
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25010492 | Acquired resistance of Mycobacterium tuberculosis to bedaquiline. | PLoS One | 2014 | https://conductscience.org/library/papers/25010492 | PubMed |
| 2 | 24567393 | Mycobacterium abscessus cording prevents phagocytosis and promotes abscess formation. | Proc Natl Acad Sci U S A | 2014 | https://conductscience.org/library/papers/24567393 | PubMed |
| 3 | 28807917 | Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected Zebrafish. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/28807917 | PubMed |
| 4 | 25331694 | Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model. | Antimicrob Agents Chemother | 2015 | https://conductscience.org/library/papers/25331694 | PubMed |
| 5 | 28242674 | In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/28242674 | PubMed |
| 6 | 25283255 | Treatment for calcium channel blocker poisoning: a systematic review. | Clin Toxicol (Phila) | 2014 | https://conductscience.org/library/papers/25283255 | PubMed |
| 7 | 29038265 | Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29038265 | PubMed |
| 8 | 28096155 | Inhibition of the β-Lactamase BlaMab by Avibactam Improves the In Vitro and In Vivo Efficacy of Imipenem against Mycobacterium abscessus. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/28096155 | PubMed |
| 9 | 24126586 | Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 2014 | https://conductscience.org/library/papers/24126586 | PubMed |
| 10 | 21292659 | Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. | Clin Infect Dis | 2011 | https://conductscience.org/library/papers/21292659 | PubMed |
| 11 | 29463541 | Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29463541 | PubMed |
| 12 | 26678435 | US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. | Thorax | 2016 | https://conductscience.org/library/papers/26678435 | PubMed |
| 13 | 17277290 | An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. | Am J Respir Crit Care Med | 2007 | https://conductscience.org/library/papers/17277290 | PubMed |
| 14 | 30323043 | Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/30323043 | PubMed |
| 15 | 17525564 | Verapamil toxicity: an unusual case report and review of the literature. | Am J Forensic Med Pathol | 2007 | https://conductscience.org/library/papers/17525564 | PubMed |
| 16 | 20071249 | Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. | J Cyst Fibros | 2010 | https://conductscience.org/library/papers/20071249 | PubMed |
| 17 | 24532601 | Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs. | J Infect Dis | 2014 | https://conductscience.org/library/papers/24532601 | PubMed |
| 18 | 26214350 | The Burden of Pulmonary Nontuberculous Mycobacterial Disease in the United States. | Ann Am Thorac Soc | 2015 | https://conductscience.org/library/papers/26214350 | PubMed |
| 19 | 20521931 | TMC207: the first compound of a new class of potent anti-tuberculosis drugs. | Future Microbiol | 2010 | https://conductscience.org/library/papers/20521931 | PubMed |
| 20 | 24515248 | Genomic reconnaissance of clinical isolates of emerging human pathogen Mycobacterium abscessus reveals high evolutionary potential. | Sci Rep | 2014 | https://conductscience.org/library/papers/24515248 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41767945 | CRISPR-based genome editing reveals the roles of efflux pumps in Mycobacterium abscessus. | mLife | 2026 | https://conductscience.org/library/papers/41767945 | PubMed |
| 41155175 | Beyond Antibiotics: Repurposing Non-Antibiotic Drugs as Novel Antibacterial Agents to Combat Resistance. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41155175 | PubMed |
| 40709198 | Interactions between gut microbiota and cardiovascular drugs: effects on drug therapeutic effect and side effect. | Front Cardiovasc Med | 2025 | https://conductscience.org/library/papers/40709198 | PubMed |
| 39766559 | Mycobacterium tuberculosis F-ATP Synthase Inhibitors and Targets. | Antibiotics (Basel) | 2024 | https://conductscience.org/library/papers/39766559 | PubMed |
| 38572960 | Efflux pump effects on levofloxacin resistance in Mycobacterium abscessus. | Antimicrob Agents Chemother | 2024 | https://conductscience.org/library/papers/38572960 | PubMed |
| 36902066 | Mycobacterium abscessus Infections in Cystic Fibrosis Individuals: A Review on Therapeutic Options. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36902066 | PubMed |
| 35420492 | In Vitro Bedaquiline and Clofazimine Susceptibility Testing in Mycobacterium abscessus. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/35420492 | PubMed |
| 34526902 | Current Molecular Therapeutic Agents and Drug Candidates for Mycobacterium abscessus. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34526902 | PubMed |
| 33790590 | Carbonyl Cyanide 3-Chlorophenylhydrazone (CCCP) Exhibits Direct Antibacterial Activity Against Mycobacterium abscessus. | Infect Drug Resist | 2021 | https://conductscience.org/library/papers/33790590 | PubMed |
| 33645845 | Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities. | Med Res Rev | 2021 | https://conductscience.org/library/papers/33645845 | PubMed |
| 33565103 | Host-directed therapy to combat mycobacterial infections. | Immunol Rev | 2021 | https://conductscience.org/library/papers/33565103 | PubMed |
| 33325009 | Are antibacterial effects of non-antibiotic drugs random or purposeful because of a common evolutionary origin of bacterial and mammalian targets? | Infection | 2021 | https://conductscience.org/library/papers/33325009 | PubMed |
| 33042066 | In vitro Study of Bedaquiline Resistance in Mycobacterium tuberculosis Multi-Drug Resistant Clinical Isolates. | Front Microbiol | 2020 | https://conductscience.org/library/papers/33042066 | PubMed |
| 32253217 | Efficacy of Bedaquiline, Alone or in Combination with Imipenem, against Mycobacterium abscessus in C3HeB/FeJ Mice. | Antimicrob Agents Chemother | 2020 | https://conductscience.org/library/papers/32253217 | PubMed |
| 32086501 | Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. | Nat Rev Microbiol | 2020 | https://conductscience.org/library/papers/32086501 | PubMed |
| 32041716 | Synergistic Interactions of Indole-2-Carboxamides and β-Lactam Antibiotics against Mycobacterium abscessus. | Antimicrob Agents Chemother | 2020 | https://conductscience.org/library/papers/32041716 | PubMed |
| 31766758 | Mycobacterium abscessus, an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31766758 | PubMed |
| 31332077 | The TetR Family Transcription Factor MAB_2299c Regulates the Expression of Two Distinct MmpS-MmpL Efflux Pumps Involved in Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/31332077 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31209005
GET https://conductscience.org/api/papers/v1/31209005/references?page=2